CN1310906C - 用作p38激酶抑制剂的吲哚类型的衍生物 - Google Patents

用作p38激酶抑制剂的吲哚类型的衍生物 Download PDF

Info

Publication number
CN1310906C
CN1310906C CNB00807724XA CN00807724A CN1310906C CN 1310906 C CN1310906 C CN 1310906C CN B00807724X A CNB00807724X A CN B00807724XA CN 00807724 A CN00807724 A CN 00807724A CN 1310906 C CN1310906 C CN 1310906C
Authority
CN
China
Prior art keywords
compound
benzyl
fluoro
methyl
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB00807724XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1351599A (zh
Inventor
B·J·马文凯尔
S·查克拉瓦蒂
J·J·佩拉马塔姆
S·杜嗄尔
Q·吕
X·梁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCOIS Inc
Original Assignee
SCOIS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/316,761 external-priority patent/US6589954B1/en
Application filed by SCOIS Inc filed Critical SCOIS Inc
Publication of CN1351599A publication Critical patent/CN1351599A/zh
Application granted granted Critical
Publication of CN1310906C publication Critical patent/CN1310906C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB00807724XA 1999-05-21 2000-05-19 用作p38激酶抑制剂的吲哚类型的衍生物 Expired - Fee Related CN1310906C (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/316,761 1999-05-21
US09/316,761 US6589954B1 (en) 1998-05-22 1999-05-21 Compounds and methods to treat cardiac failure and other disorders
US15459499P 1999-09-17 1999-09-17
US60/154,594 1999-09-17
US20260800P 2000-05-09 2000-05-09
US60/202,608 2000-05-09
PCT/US2000/014003 WO2000071535A1 (en) 1999-05-21 2000-05-19 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE

Publications (2)

Publication Number Publication Date
CN1351599A CN1351599A (zh) 2002-05-29
CN1310906C true CN1310906C (zh) 2007-04-18

Family

ID=27387611

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB00807724XA Expired - Fee Related CN1310906C (zh) 1999-05-21 2000-05-19 用作p38激酶抑制剂的吲哚类型的衍生物

Country Status (20)

Country Link
EP (1) EP1178983B1 (https=)
JP (1) JP2003500403A (https=)
KR (1) KR100743377B1 (https=)
CN (1) CN1310906C (https=)
AT (1) ATE376547T1 (https=)
AU (2) AU772295B2 (https=)
BG (1) BG106091A (https=)
BR (1) BR0011274A (https=)
CA (1) CA2372567A1 (https=)
CZ (1) CZ20014126A3 (https=)
DE (1) DE60036868D1 (https=)
HR (1) HRP20010854A2 (https=)
HU (1) HUP0201261A3 (https=)
IL (1) IL146309A0 (https=)
MX (1) MXPA01011976A (https=)
NO (1) NO20015655L (https=)
NZ (1) NZ515285A (https=)
PL (1) PL352032A1 (https=)
SK (1) SK16482001A3 (https=)
WO (1) WO2000071535A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024179405A1 (zh) * 2023-02-27 2024-09-06 上海交通大学 一类肉桂酰胺衍生物及其应用

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541477B2 (en) 1999-08-27 2003-04-01 Scios, Inc. Inhibitors of p38-a kinase
AU2001241927A1 (en) * 2000-02-28 2001-09-12 Scios Inc. Inhibitors of p38-alpha kinase
US6573262B2 (en) 2000-07-10 2003-06-03 Bristol-Myers Sqibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
EP1339708A2 (en) 2000-11-20 2003-09-03 Scios Inc. Indole-type inhibitors of p38 kinase
DE60125980T2 (de) * 2000-11-20 2007-10-25 Scios Inc., Sunnyvale P38kinase-inhibitoren vom piperidin/piperazin-typ
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
EP1363705B9 (en) * 2001-02-02 2012-11-07 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
CA2460345A1 (en) 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer
CA2460347A1 (en) 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 3-glyoxlylamideindoles for treating cancer
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
WO2003041644A2 (en) * 2001-11-09 2003-05-22 Scios Inc. Method to treat cystic fibrosis
MXPA04004830A (es) * 2001-11-22 2004-07-30 Ono Pharmaceutical Co Compuestos derivados de piperidin-2-ona, y composiciones farmaceuticas que los contienen como ingredientes activos.
CA2479520A1 (en) * 2002-04-05 2003-10-16 Birgit Jung P38 kinase inhibitors for treating mucus hypersecretion_
GB0209818D0 (en) 2002-04-30 2002-06-05 Koninkl Philips Electronics Nv Antenna arrangement
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
WO2004019873A2 (en) 2002-08-29 2004-03-11 Scios Inc. Methods of promoting osteogenesis
AU2003268464A1 (en) 2002-09-03 2004-03-29 Scios Inc. INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
AU2003279230A1 (en) * 2002-10-09 2004-05-04 Scios Inc. AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE
JP2006510654A (ja) * 2002-12-06 2006-03-30 サイオス・インコーポレーテツド 糖尿病を処置する方法
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7521447B2 (en) 2003-03-03 2009-04-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
WO2004101529A1 (ja) * 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
WO2005030091A2 (en) 2003-09-25 2005-04-07 Scios Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
GB0402140D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402138D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
EP2258704A1 (en) 2004-10-19 2010-12-08 ArQule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
RS52298B (sr) 2006-01-31 2012-12-31 Array Biopharma Inc. Inhibitori kinaze i postupak njihove upotrebe
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
WO2008024391A1 (en) * 2006-08-22 2008-02-28 Scios Inc. Pharmaceutical formulations of an indole-type derivative and related methods of use
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
AR072008A1 (es) * 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US8114894B2 (en) 2008-12-03 2012-02-14 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
SI2648516T1 (sl) 2010-12-06 2019-01-31 Aclaris Therapeutics, Inc. Substituirane spojine piridinon-piridinila
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
WO2012078673A1 (en) 2010-12-06 2012-06-14 Confluence Life Sciences, Inc. Substituted pyridine urea compounds
US8507499B2 (en) 2010-12-06 2013-08-13 Confluence Life Sciences, Inc. Substituted indole/indazole-pyrimidinyl compounds
US9056110B2 (en) 2011-12-06 2015-06-16 Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl-pyrimidinyl compounds
HUE054178T2 (hu) 2013-06-07 2021-08-30 Aclaris Therapeutics Inc Metil/fluor-piridinil-metoxi-szubsztituált piridinon-piridinil-vegyületek és fluor-pirimidinil-metoxi-szubsztituált piridinon-piridinil-vegyületek
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
KR20220161396A (ko) 2020-03-27 2022-12-06 어클라리스 쎄라퓨틱스, 인코포레이티드 치환된 피리디논-피리디닐 화합물의 제조, 조성물, 및 결정형
CN115745864B (zh) 2021-09-03 2025-10-10 深圳零一生命科技有限责任公司 吲哚类化合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028292A1 (en) * 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
WO1999000357A1 (en) * 1997-06-27 1999-01-07 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283248A (en) * 1989-11-21 1994-02-01 Hoffmann-La Roche Inc. Amino substituted pyrimido[1,6-2]benzimidazoles
CA2028530A1 (en) * 1989-11-21 1991-05-22 Christian Hubschwerlen Substituted pyrimidobenzimidazole derivatives
JP2001506230A (ja) * 1996-08-09 2001-05-15 スミスクライン・ビーチャム・コーポレイション 新規ピペラジン含有化合物
KR100605140B1 (ko) * 1998-05-22 2006-07-28 싸이오스 인크 심장병 및 다른 질병을 치료하기 위한 헤테로 고리 화합물및 그 치료 방법
MXPA01002173A (es) * 1998-08-28 2003-07-14 Scios Inc Inhibidores de p38-alfa cinasa.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028292A1 (en) * 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
WO1999000357A1 (en) * 1997-06-27 1999-01-07 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024179405A1 (zh) * 2023-02-27 2024-09-06 上海交通大学 一类肉桂酰胺衍生物及其应用

Also Published As

Publication number Publication date
DE60036868D1 (de) 2007-12-06
NZ515285A (en) 2004-01-30
CN1351599A (zh) 2002-05-29
AU772295B2 (en) 2004-04-22
KR100743377B1 (ko) 2007-07-30
CA2372567A1 (en) 2000-11-30
HRP20010854A2 (en) 2003-04-30
EP1178983B1 (en) 2007-10-24
NO20015655L (no) 2002-01-18
BR0011274A (pt) 2002-02-26
MXPA01011976A (es) 2002-05-06
BG106091A (en) 2002-06-28
AU2004203356A1 (en) 2004-08-19
WO2000071535A1 (en) 2000-11-30
JP2003500403A (ja) 2003-01-07
PL352032A1 (en) 2003-07-28
IL146309A0 (en) 2002-07-25
ATE376547T1 (de) 2007-11-15
HUP0201261A3 (en) 2003-12-29
KR20020019919A (ko) 2002-03-13
AU5442400A (en) 2000-12-12
EP1178983A1 (en) 2002-02-13
HUP0201261A2 (en) 2002-08-28
NO20015655D0 (no) 2001-11-20
SK16482001A3 (sk) 2002-04-04
CZ20014126A3 (cs) 2002-03-13

Similar Documents

Publication Publication Date Title
CN1310906C (zh) 用作p38激酶抑制剂的吲哚类型的衍生物
CN1229351C (zh) 杂环化合物和治疗心力衰竭及其它疾病的方法
CN1290844C (zh) 用作蛋白激酶抑制剂的二氢吲哚酮衍生物
CN1124262C (zh) 用作内皮缩血管肽受体拮抗剂的吲哚衍生物
CN1072220C (zh) 作为神经激肽受体拮抗剂的1－苯甲酰基－2－(吲哚基－3－烷基)－哌嗪衍生物
CN1198819C (zh) 苯并咪唑衍生物
CN1067054C (zh) 1H-吲哚-3-乙醛酰胺sPLA2抑制剂
CN1145616C (zh) 新的氨基三唑化合物,其制备方法及包含它们的药物组合物
CN1310907C (zh) 杂环化合物和以其为有效成分的抗肿瘤药
CN1234688C (zh) 3－芳酰基吲哚及其作为cb2受体激动剂的应用
CN1713910A (zh) 作为p38激酶抑制剂的氮杂吲哚衍生物
CN1222511C (zh) 作为5－羟色胺－6配体的1－芳基－或1－烷基磺酰基－杂环基吲哚
CN1726029A (zh) 作为纤溶酶原激活物抑制剂 － 1(pa i－1 )的抑制剂的取代二氢吡喃并吲哚－3, 4－二酮衍生物和3－氧代乙酸取代的2－羟基甲基吲哚衍生物
CN1549814A (zh) 作为1型纤溶酶原激活物抑制剂(pai-1)的抑制剂的取代萘基吲哚衍生物
CN1668590A (zh) 用作5－羟色胺－6配体的1－杂环基烷基－3－磺酰基－吲哚或－吲唑衍生物
CN1250542C (zh) 具有抗肿瘤活性的2－(1h－吲哚－3－基)－2－氧代－乙酰胺
CN1140709A (zh) 被取代的N-(吲哚-2-羰基)-β-丙氨酰胺与作为抗糖尿病药的衍生物
CN1060841A (zh) 喹唑啉衍生物及其制备方法
CN1374082A (zh) 糖原磺酸化酶抑制剂的用途
CN1035113A (zh) 用于治疗的杂环化合物
CN1560035A (zh) 5－羟基吲哚－3－羧酸脂类衍生物
CN1203587A (zh) 新的杂环衍生物及其医药用途
CN1119856A (zh) Hiv逆转录酶抑制剂
CN1771244A (zh) 作为5－羟色胺－6配体的杂环－3－磺酰基吲唑
CN87103504A (zh) 杂环羧酰胺

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070418